Alnylam Pharmaceuticals, Inc. (ALNY) on Focus After Forming Double Top

December 7, 2017 - By Dolores Ford

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.70, from 0.82 in 2017Q1. It is positive, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Susquehanna Intll Gru Ltd Liability Partnership stated it has 101,623 shares or 0% of all its holdings. Suffolk Cap Management Ltd invested 1.2% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Commonwealth Equity Services Inc holds 7,299 shares or 0% of its portfolio. Arrowmark Colorado Ltd Liability Corp invested 0.53% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Vanguard Grp Inc reported 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Voloridge Inv Limited Co accumulated 136,662 shares or 0.27% of the stock. Emerald Advisers Pa accumulated 0.06% or 17,322 shares. Bnp Paribas Arbitrage Sa holds 0% or 13,000 shares. Brighton Jones Ltd Liability invested in 4,011 shares. Perceptive Advisors Ltd Company reported 7.36% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 3,512 are owned by Zurcher Kantonalbank (Zurich Cantonalbank). Moreover, Td Asset has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 129,918 shares. Massachusetts-based Fmr Ltd Liability has invested 0.14% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bancorp Of Mellon has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 333,942 shares. M&T Commercial Bank reported 4,130 shares stake.

The chart of Alnylam Pharmaceuticals, Inc. (ALNY) shows a double top with $139.03 target or 8.00 % above today’s $128.73 share price. The 5 months chart pattern indicates low risk for the $12.77B company. It was reported on Dec, 7 by Finviz.com. If the $139.03 price target is reached, the company will be worth $1.02B more. Double tops are rare but powerful chart patterns.

The stock increased 3.34% or $4.16 during the last trading session, reaching $128.73. About 754,726 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since December 7, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.36 EPS, down 3.03 % or $0.04 from last year’s $-1.32 per share. After $-1.34 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.49 % negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 84 analyst reports since August 7, 2015 according to SRatingsIntel. The company was initiated on Friday, October 23 by Jefferies. Piper Jaffray maintained the stock with “Buy” rating in Thursday, November 2 report. The rating was maintained by Credit Suisse with “Outperform” on Friday, November 3. As per Thursday, September 21, the company rating was maintained by Credit Suisse. Needham maintained it with “Buy” rating and $152.0 target in Friday, November 3 report. The stock has “Buy” rating by BMO Capital Markets on Thursday, August 10. Goldman Sachs upgraded the shares of ALNY in report on Monday, October 2 to “Buy” rating. The rating was downgraded by TheStreet to “Hold” on Saturday, August 22. The firm earned “Buy” rating on Monday, December 19 by Chardan Capital Markets. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Equal-Weight” rating by Barclays Capital on Thursday, October 6.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “Commit To Buy Alnylam Pharmaceuticals At $70, Earn 11.4% Using Options” on November 28, 2017, also Fool.com with their article: “Why Alnylam Pharmaceuticals Rose 12.7% in November” published on December 06, 2017, Businesswire.com published: “Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock …” on November 16, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam Sets Its Eyes On The Finish Line” published on November 20, 2017 as well as Fool.com‘s news article titled: “Alnylam Pharmaceuticals, Inc.’s Pipeline Progresses, Approval Next” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.